AI Access Brief Podcast

AI Access Brief Podcast

By Carl HaakonBusinessManagement
Download on the App Store

AI Access Brief Podcast episodes

  • Orphan Dominance and Oral Semaglutide Market Shifts
    Episode 23 — 06 June 2026
    Marcus and Sara examine the CHMP's May session showing 42% orphan designation rates and debate whether oral semaglutide represents genuine innovation or market expansion. They clash over emergency regulatory collaboration priorities and disagree on JCA capacity constraints for specialty medicines.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    6 min
  • DMD Access Breakthrough and CHMP Pipeline Shift
    Episode 22 — 05 June 2026
    NICE approves third DMD treatment givinostat via Innovative Medicines Fund while CHMP's May output signals structural shift toward rare disease therapies. ISPOR 2026 highlights HEOR's expanding role in policy and value frameworks amid accelerating orphan designation trends.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    5 min
  • RNA Breakthroughs, Critical Medicines Act, and Evidence Judgment Era
    Episode 21 — 04 June 2026
    European Parliament and Council reach provisional agreement on Critical Medicines Act while EMA approves first RNA-based veterinary vaccine. ISPOR's latest trends report signals the shift from data production to evidence judgment as the new evaluation criterion.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    6 min
  • First-in-Class HEOR Challenges and Regulatory Framework Shifts
    Episode 20 — 03 June 2026
    Multiple first-in-class therapies create new HEOR value demonstration challenges while industry increasingly funds academic research to support policy positions. EMA's annual report reveals optimization of medicines assessments and HTA regulation coordination progress.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    6 min
  • CHMP Approvals Signal Shift, JCA Device Rollout Begins
    Episode 19 — 02 June 2026
    CHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 trends report.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    5 min
  • Medical Device JCAs Launch and NICE Methodology Shifts

    Episode 18 — 01 June 2026 Medical device JCAs begin this month as NICE refines implementation guidance and biosimilar value assessment approaches. The hosts disagree on whether NICE's procedural simplifications strengthen or weaken evidence standards. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast  GS1M3fTk8J53NF2ecagc

    6 min
  • CHMP Rare Disease Pipeline and NICE Threshold Implementation
    Episode 17 — 31 May 2026
    EMA's CHMP approved eight medicines in May with heavy focus on rare diseases and specialty indications. NICE reveals implementation details for threshold increase while JCA capacity constraints intensify with only 17 scientific advice slots available.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    6 min
  • Device JCAs Launch, NICE Prioritisation, and MFN Reality Check
    Episode 16 — 30 May 2026
    Medical device JCAs launch in June as NICE implements new prioritisation framework. Trump's MFN commitments clash with reality as pharma raises prices on over 350 products.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    7 min
  • Critical Medicines Act, AI Tops HEOR Trends, NICE Advice ROI
    Episode 15 — 29 May 2026
    The EU Critical Medicines Act positions EMA as central authority for supply chain assessments across 200+ substances. AI jumps to #1 in ISPOR trends while NICE advice cuts appraisal timelines by three months.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    7 min
  • EQ-5D-5L Update Reshapes Cancer Economics
    Episode 14 — 28 May 2026
    NICE's first QALY valuation update in over a decade shows cancer medicines becoming more cost-effective while quality-of-life therapies face higher ICERs. Meanwhile, JCA expansion into medical devices and new NICE prioritisation frameworks signal tighter evidence requirements across the board.
    Hosted by Marcus and Sara.
    Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
    Full transcript and sources at outcomes-analytica.no/podcast
    6 min

About AI Access Brief Podcast

From the publisher's feed

AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…